Zacks.com on MSN15h
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate
Key Takeaways Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's ...
GlobalData on MSN22h
Amgen speaks out about bone density concerns with obesity drug
Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...
Stocks on Sale: Sezzle, Mosaic, and Amgen
After Sezzle (SEZL) rallied from $200 to over $400, the stock lost 13.87% on Tuesday. The stock drop could continue, depending on how many investors sell to lock in their profits. Sezzle has strong ...